Lecture

Parkinson's Disease Drug Development

Description

This lecture by the instructor covers the preclinical strategy for developing drugs in Parkinson's Disease, including establishing a research and development organization, disease representation, genetic evidence, and potential therapeutic strategies. It also discusses target identification, drug modality selection, molecular mechanisms like a-syn aggregation, building assay pipelines, and external innovation partnerships.

Official source

https://mediaspace.epfl.ch/media/0_x6vbv3et

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Ontological neighbourhood

Health sciences

Neurology: Neurodegenerative disease

Related lectures (37)

Explores protein aggregation in neurodegenerative diseases, emphasizing the need to rethink treatment strategies and understand the role of post-translational modifications.

Explores genetic factors in Parkinson's disease, focusing on a-synuclein, Parkin, and PINK1, and their impact on mitochondrial quality control.

Explores Parkinson's disease, covering symptoms, treatments, cognitive impairments, and hallucinations.

Explores cryo-EM techniques for studying protein aggregation in neurodegenerative diseases, focusing on a-synuclein.

Delves into Cryo-EM's role in studying Parkinson's Disease and protein structures at the nano-level.